Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV5-hRKp.RPGR in X-linked Retinitis Pigmentosa
NCT04794101Phase 3Active, not recruiting
- Sponsor
- MeiraGTx
- Start
- Dec 2020
- Primary completion
- Sep 2029
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 11
01
Overview
A Phase 3 trial of botaretigene sparoparvovec in X-linked retinitis pigmentosa (XLRP), sponsored by MeiraGTx. Started Dec 2020; status: active, not recruiting.
02
Drugs
botaretigene sparoparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on NCT04794101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794101.